Oral Insulin: Breakthrough Innovation at Biocon Harvard Case Solution & Analysis

This case deals with the initiation challenges of a medium sized company (under $1 billion) in an emerging market (India), particularly the challenges of product development and commercialization. The management has to decide how exactly to proceed with a promising innovative convention for oral insulin - a bright therapeutic area both when it comes to fiscal returns together with societal impact.  The corporation had used up numerous years of R&D in getting the drug through Phase I and Phase II trials, and was incoming the most serious stage, Phase III. 

Oral Insulin Breakthrough Innovation at Biocon Case Study Solution

The case is set in 2009, a period which was punctuate with a lot of financial ambiguity. Students are requested to decide if Biocon should go ahead with Phase III, and in that case, whether it should be done globally or locally and with a partner or in isolation.

PUBLICATION DATE: August 05, 2011 PRODUCT #: W11276-PDF-ENG

This is just an excerpt. This case is about STRATEGY & EXECUTION

Oral Insulin: Breakthrough Innovation at Biocon Case Solution Other Similar Case Solutions like

Oral Insulin: Breakthrough Innovation at Biocon

Share This